Long-term Outcomes of Globe-Preserving Surgery With Proton Beam Radiation for Adenoid Cystic Carcinoma of the Lacrimal Gland

Wolkow, Natalie; Jakobiec, Frederick A.; Lee, Hang; Sutula, Francis C.

doi:10.1016/j.ajo.2018.07.024

Cited by 45 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 3 years OS, local PFS and PFS rates were 78, 70, and 58%, respectively. These survival rates are close to these reported by recent retrospectives studies with modern radiotherapy modalities (5,14,15). Table 5 reports outcomes and toxicities from 11 recent retrospective studies (5,(14)(15)(16)(17)(18)(19)(20)(21)(22)(23).…”

Section: Discussionsupporting

confidence: 78%

“…This makes direct comparisons very difficult. Wolkow (5), reported in 2018, a similar 3 years OS rate of 80% with an adjuvant high dose proton-photon mix irradiation but with higher PFS rate than us (75% for 5years PFS vs. 38% in our study). Nevertheless, our patients had a more advanced disease which could explain the shorter PFS reported in our study in comparison with Wolkow's.…”

Section: Discussionsupporting

confidence: 71%

“…Most of patients (n = 12) were treated with a double scattering technical (DS), with 3 dose levels as described above and five beams, reduction fields included (median n = 5 [4][5][6] Overall survival median was not reached (Figure 2, Table 2). On univariate analysis, none of the tested factors (sex, age, TNM stage, quality of upfront surgery, volume of high risk CTV, Time From last surgery to irradiation) were predicted of local PFS, PFS, or OS.…”

Section: Radiotherapy Modalitiesmentioning

confidence: 99%

“…Previous reports on the effects of proton beam radiation (PBR) on lacrimal gland carcinoma are available but present several limits (5)(6)(7): heterogeneous histologic types are included in the same study, patients are treated with a mix of photon/proton irradiation, or ACC subgroup is often a small sample of the cohort. A recent retrospective study reported higher survival and lower recurrence rate, by using modern high dose proton-photon adjuvant irradiation in comparison with historical series, thus, supporting a rationale for high dose proton irradiation (5). In this published study 17 of the 18 included patients received a large dose of PBR (range 52.5 to 60CGE), as well as a smaller dose of photon radiation (range 12 to 23.4 CGE), administered by a linear accelerator (LINAC), for a total radiation dose of 71-76 CGE.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Adenoid Cystic Carcinoma of the Lacrimal Gland: High Dose Adjuvant Proton Therapy to Improve Patients Outcomes

et al. 2020

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 78%

Section: Discussionsupporting

confidence: 71%

Section: Radiotherapy Modalitiesmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Adenoid Cystic Carcinoma of the Lacrimal Gland: High Dose Adjuvant Proton Therapy to Improve Patients Outcomes

et al. 2020

View full text Add to dashboard Cite

“…Dabei zeigt neben der konventionellen Strahlentherapie auch die Hochdosisprotonenbestrahlung gute Ergebnisse, wie Wolkow et al an 18 Patienten (davon 4 Kinder mit einem mittleren Alter von 12 Jahren) nach bulbuserhaltender Chirurgie mit adjuvanter Hochdosisprotonenbestrahlung zeigen konnten. Die Nebenwirkungen entsprechen hauptsächlich denen der konventionellen Therapie mit Optikusneuropathie, Retinopathie, Keratopathie und Kataraktentwicklung [5].…”

Section: Introductionunclassified

Therapieoptionen bei adenoidzystischem Tränendrüsenkarzinom – Fallserie und aktueller Literaturüberblick

Mihailovic

Elges

Glitz

et al. 2018

Klin Monatsbl Augenheilkd

View full text Add to dashboard Cite

ZusammenfassungDas adenoidzystische Karzinom der Tränendrüse (ACC) stellt einen seltenen malignen orbitalen Tumor mit insgesamt schlechter Prognose dar. Derzeitige Therapieansätze mit radikaler und lokaler Chirurgie, adjuvanter Bestrahlung und neoadjuvanter intraarterieller Chemotherapie werden kontrovers diskutiert. Wir präsentieren 3 Fälle von Patienten mit ACC mit unterschiedlichen Therapiekonzepten und diskutieren diese mit aktuellen Empfehlungen aus der Literatur.

show abstract

Outcomes of orbital exenteration for craniofacial lesions

Traylor

Christiano

Esmaeli

et al. 2021

Cancer

View full text Add to dashboard Cite

BACKGROUND Orbital exenteration (OE) is an ablative procedure used in the management of malignancies of the orbit of either primary or secondary origin. Publications evaluating this procedure have suffered from small patient numbers, heterogeneity of pathologies, and poor patient follow‐up. The purpose of this study was to assess patient outcomes in a large cohort of patients undergoing OE at a tertiary cancer center. METHODS A retrospective review was conducted of 180 consecutive patients who underwent OE at the authors' institution. Overall survival (OS) was the primary end point measured in the study. Time to locoregional recurrence (progression‐free survival [PFS]) and disease‐free survival were secondary end points. RESULTS Between the years 1993 and 2011, 180 consecutive patients received OE for craniofacial malignancy at the authors' institution. The median follow‐up for the cohort was 9.7 years (116 months). The median OS was 73 months, and the median PFS was 96 months. The presence of perineural invasion was associated with shorter OS (P = .01) and PFS (P < .01). Magnetic resonance imaging was predictive of perineural invasion (P < .01). Positive margins were associated with shorter PFS than negative margins (P < .01) but with no change in OS (P = .15). The overall complication rate was 15%. The major complication rate (Clavien‐Dindo 3b or greater) was 2.8% (n = 5), and there was 1 death observed (0.6%). CONCLUSIONS Used judiciously in the setting of a multidisciplinary management plan, OE for tumor control is a safe therapy. LAY SUMMARY Between the years 1993 and 2011, 180 consecutive patients received orbital exenteration for craniofacial malignancy at the MD Anderson Cancer Center. The median follow‐up for the cohort was 9.7 years. The presence of perineural invasion was associated with shorter overall survival (P = .01) and progression‐free survival (P < .01). Magnetic resonance imaging was predictive of perineural invasion (P < .01). Positive margins were associated with shorter progression‐free survival than negative margins (P < .01). The overall complication rate was 15%. The major complication rate (Clavien‐Dindo 3b or greater) was 2.8% (n = 5).

show abstract

Long-term Outcomes of Globe-Preserving Surgery With Proton Beam Radiation for Adenoid Cystic Carcinoma of the Lacrimal Gland

Cited by 45 publications

References 28 publications

Adenoid Cystic Carcinoma of the Lacrimal Gland: High Dose Adjuvant Proton Therapy to Improve Patients Outcomes

Adenoid Cystic Carcinoma of the Lacrimal Gland: High Dose Adjuvant Proton Therapy to Improve Patients Outcomes

Therapieoptionen bei adenoidzystischem Tränendrüsenkarzinom – Fallserie und aktueller Literaturüberblick

Outcomes of orbital exenteration for craniofacial lesions

Contact Info

Product

Resources

About